WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "a45835f4-e47e-4cad-bdf9-23af2401246d"}, "_deposit": {"created_by": 3, "id": "13102", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "13102"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00013102", "sets": ["1134"]}, "author_link": ["20750", "20756", "20751", "20753", "20754", "20752", "20755"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2003-01-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "108", "bibliographicPageStart": "105", "bibliographicVolumeNumber": "44", "bibliographic_titles": [{"bibliographic_title": "Journal of Nuclear Medicine"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "This study used PET to measure the time course of the brain concentration of 18F-labeled N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel antidementia drug, after oral administration to conscious rhesus monkeys. Methods: Three young-adult male rhesus monkeys were tested. FK960 (0.1 mg/kg) containing about 370 MBq of 18F-FK960 was administered orally to each monkey. Dynamic PET images were acquired for 4 h from 5 min after the administration. Arterial blood samples were withdrawn during PET scanning and were analyzed by an automatic well γ-counter and thin-layer chromatography to determine the time course of authentic 18F-FK960 activity concentration in plasma. FK960 concentrations in brain and plasma were calculated in units of mol/L using the specific activity of FK960 preparations. Results: 18F-FK960 penetrated the blood-brain barrier and underwent perfusion-dependent distribution in the entire brain. Maximal concentrations in the brain and plasma were 1.11 ± 0.30 x 10-7 mol/L (at 3.0 ± 0.6 h after administration) and 4.04 ± 1.29 x 10-7 mol/L (at 2.0 ± 1.1 h after administration), respectively. Conclusion: We succeeded in measuring the FK960 concentration in the brains of conscious monkeys and in plasma after oral administration at a dose of 0.1 mg/kg. The results suggested that this method can measure the FK960 concentration in the human brain, and a potential use of the PET technique in drug development was demonstrated.", "subitem_description_type": "Abstract"}]}, "item_4_description_5": {"attribute_name": "提供者所属", "attribute_value_mlt": [{"subitem_description": "金沢大学大学院医学系研究科", "subitem_description_type": "Other"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "THE SOCIETY OF NUCLEAR MEDICINE INC"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0161-5505", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Noda, Akihiro"}], "nameIdentifiers": [{"nameIdentifier": "20750", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takamatsu, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "20751", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murakami, Yoshihiro"}], "nameIdentifiers": [{"nameIdentifier": "20752", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yajima, Kazuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "20753", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsumi, Mitsuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "20754", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichise, Rikiya"}], "nameIdentifiers": [{"nameIdentifier": "20755", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishimura, Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "20756", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-03"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-NODA-A-105.pdf", "filesize": [{"value": "128.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 128400.0, "url": {"label": "ME-PR-NODA-A-105.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/13102/files/ME-PR-NODA-A-105.pdf"}, "version_id": "c1d435d5-a6ed-45b5-b540-cb3450aa6351"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Antidementia drug", "subitem_subject_scheme": "Other"}, {"subitem_subject": "N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate", "subitem_subject_scheme": "Other"}, {"subitem_subject": "PET", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pharmacokinetics", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rhesus monkey", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys"}]}, "item_type_id": "4", "owner": "3", "path": ["1134"], "permalink_uri": "http://hdl.handle.net/2297/2782", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-03"}, "publish_date": "2017-10-03", "publish_status": "0", "recid": "13102", "relation": {}, "relation_version_is_last": true, "title": ["Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys"], "weko_shared_id": 3}
Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys
http://hdl.handle.net/2297/2782
http://hdl.handle.net/2297/2782f1dd95b0-97b8-4393-aae3-35e3a837ae29
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-NODA-A-105.pdf (128.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-03 | |||||
タイトル | ||||||
タイトル | Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Noda, Akihiro
× Noda, Akihiro× Takamatsu, Hiroyuki× Murakami, Yoshihiro× Yajima, Kazuyoshi× Tatsumi, Mitsuyoshi× Ichise, Rikiya× Nishimura, Shintaro |
|||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学大学院医学系研究科 | |||||
書誌情報 |
Journal of Nuclear Medicine 巻 44, 号 1, p. 105-108, 発行日 2003-01-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0161-5505 | |||||
出版者 | ||||||
出版者 | THE SOCIETY OF NUCLEAR MEDICINE INC | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | This study used PET to measure the time course of the brain concentration of 18F-labeled N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel antidementia drug, after oral administration to conscious rhesus monkeys. Methods: Three young-adult male rhesus monkeys were tested. FK960 (0.1 mg/kg) containing about 370 MBq of 18F-FK960 was administered orally to each monkey. Dynamic PET images were acquired for 4 h from 5 min after the administration. Arterial blood samples were withdrawn during PET scanning and were analyzed by an automatic well γ-counter and thin-layer chromatography to determine the time course of authentic 18F-FK960 activity concentration in plasma. FK960 concentrations in brain and plasma were calculated in units of mol/L using the specific activity of FK960 preparations. Results: 18F-FK960 penetrated the blood-brain barrier and underwent perfusion-dependent distribution in the entire brain. Maximal concentrations in the brain and plasma were 1.11 ± 0.30 x 10-7 mol/L (at 3.0 ± 0.6 h after administration) and 4.04 ± 1.29 x 10-7 mol/L (at 2.0 ± 1.1 h after administration), respectively. Conclusion: We succeeded in measuring the FK960 concentration in the brains of conscious monkeys and in plasma after oral administration at a dose of 0.1 mg/kg. The results suggested that this method can measure the FK960 concentration in the human brain, and a potential use of the PET technique in drug development was demonstrated. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |